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Previous morphologic observations have suggested 
abnormalities in the elastic fibers in a number of both 
inherited and acquired diseases. Recent progress made 
in understanding of the normal biology of elastin has 
allowed us to examine these diseases by biochemical 
means. In this review we are discussing the current 
status of the research on the elastin diseases with par­
ticular emphasis on clinical conditions affecting skin, as 
for example, cutis laxa, pseudoxanthoma elasticum, and 
the Buschke-Ollendorff syndrome. In addition, we pres­
ent new data which appears to be the first demonstration 
of an elastin abnormality in the Marfan syndrome. 
Elastic fibers of the connective tissues form a network which, 
at least in part, is responsible for the elastic properties of organs 
[1-4]. The concentrations of the elastic fibers in different tissues 
are highly variable; their relative concentrations are highest in 
aorta and related cardiovascular tissues. They are also abun­
dantly present in the lungs, achilles tendon, and most notably 
in the bovine ligamentum nuchae. In contrast, the elastic fibers 
are only a minor component in tissues such as skin: in adult 
human skin, the elastin content is clearly less than two percent 
of the dry weight of the tissue [3,5]. 
Previous morphologic observations have suggested that elas­
tic fibers are abnormal in a variety of both inherited and 
acquired connective tissue diseases [3,4]. Recent advances made 
in the understanding of the normal biology of the elastic fibers 
have provided us with the means to investigate these disease 
processes by biochemical techniques. 
NORMAL BIOLOGY OF THE ELASTIC FIBERS 
Structure 
Ultrastructural examination of the elastic fibers reveals a 
complex structure consisting of 2 different components (Fig 1) 
[6,7]. The major component, elastin, a relatively well charac­
terized connective tissue protein, has an amorphous ultrastruc­
tural appearance. The amorphous elastin is surrounded by a 
second component, the microfibrils, which are usually 10-12 
nm in diameter (Fig IB). These microfibrils consist of so-called 
elastic tissue microfibrillar protein or proteins. The relative 
concentrations of elastin and the microfibrillar component vary 
during embryonic development; the newly developed fibers in 
young embryos are composed almost exclusively of the micro-
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fibrillar component, but during development the proportion of 
elastin increases progressively and in a fully developed fiber 
more than 90% is elastin [6,7]. 
Currently, very little is known of the biochemistry of the 
microfibrillar component. For example, it is not known whether 
it consists of a single type of protein or whether there is a family 
of microfibrillar proteins [8,9]. In contrast, the structure of 
elastin is well characterized [3-5,10,11]. The basic unit of elastin 
is a linear polypeptide known variably as "soluble elastin," 
"tropoelastin," or "elastin." This polypeptide has an approxi­
mate molecular weight of 72,000 and its amino acid composition 
has several characteristic features: For example, the relative 
contents of alanine and valine are exceptionally high as com­
pared to proteins in general. Nonpolar amino acids comprise 
more than half of the total amino acid residues, imparting the 
characteristic hydrophobic nature to the protein. The content 
of glycine in elastin is also high, consisting of about one-third of 
total amino acid residues. Sequence studies have demonstrated 
that in elastin, glycine is unevenly distributed along the poly­
peptide chains and there are, for example, several repeating 
sequences consisting of lys-ala-ala-Iys and Iys-ala-ala-ala-Iys 
[12]. Elastin also contains some hydroxyproline residues which 
are formed through post-translational hydroxylation of some 
prolyl residues [13]. The relative content of this amino acid is, 
however, considerably less than that of collagen and varies 
between tissues and different animal species. The amino acid 
composition of elastin is devoid of hydroxylysine, tryptophan, 
histidine and methionine. Cystine also appears to be absent in 
extracellular elastin, although some of the in vitro translation 
products of elastin messenger-RNA may contain a few residues 
of cystine [14]. 
At present, it is unknown if elastin consists of a group of 
genetically distinct proteins, as in the case of collagen [ 15]. 
There are, however, some observations in the recent literature 
suggesting the possibility that multiple forms of elastin with 
distinct primary sequences exist. First, in one report of the in 
vitro translation of elastin messenger-RNA produced two kinds 
of elastin-like polypeptides with slightly different molecular 
weights and amino acid compositions [14]. Secondly, based on 
variable amounts of valyl-prolyl dipeptides in elastin obtained 
from different tissues, it has been suggested that elastin may 
exist in genetically distinct forms [16]. The clarification of this 
point, however, awaits further studies employing peptide map­
ping and amino acid sequencing. If different genetic types of 
elastin do exist, they may play a significant role in determining 
the elastic properties of various tissues. 
A unique feature of elastin is the presence of desmosines, 
highly stable covalent cross-links, which connect the individual 
elastin polypeptides into a continuous network [10,17]. The 
presence of desmosines, together with other minor cross-link 
compounds, are responsible for this protein's elastic character­
istics and highly insoluble nature. The relative content of 
desmosine and its isomer, isodesmosine, is relatively constant 
in normal elastic fibers, being approximately 2 residues per 1000 
amino acids [18,19]. Thus, an assay of desmosine can be em­
ployed to determine the elastin concentrations in tissues. 
The formation of desmosine occurs in the extracellular space 
and the initial step is the oxidative deamination of lysyl residues 
to the corresponding aldehydes, called allysines (Table I). This 
converSIOn is catalyzed by a copper-requiring enzyme, lysyl 
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oxidase [20]. The desmosines are then formed by subsequent 
nonenzymatic fusion of 3 allysines and a fourth unmodified 
lysyl residue [3]. The allysine and lysine residues may belong 
to separate polypeptides, and thus the desmosines link the 
individual elastin peptide chains into a continuous network. 
FIG 1. Structure of normal elastic fibers in dermis. A, By histopath­
ologic examination the elastic fibers appear black and wavy, inter­
spersed between collagen fibers (Verhoeff-van Gieson, reduced from X 
350). B, Electron microscopic appearance of the fibers. Note the dense 
microfibrils embedded in the amorphous elastin matrix (reduced from 
x 16,000). (Reproduced with permission from Ryhanen and Uitto [5]). 
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Biosynthesis 
The major cell type responsible for elastin synthesis appears 
to be the smooth muscle cell [21,22]. In addition, endothelial 
cells, ligamentum nuchae fibroblasts, and fibrocartilagenous 
chondroblasts have been shown to synthesize elastin in vitro 
[23-25]' The production of elastin by cells follows the same 
basic principles as the synthesis of proteins in general (Table 
I). The translation of messenger-RNA coding for elastin poly­
peptides takes place on the polyribosomes of rough endoplasmic 
reticulum (RER), and the nascent polypeptide chains are re­
leased into the cisternae of RER. The mechanism of the secre­
tion of elastin polypeptides from the cisternae of RER to the 
extracellular space is not clear in detail. It is possible, however, 
that elastin is secreted via Golgi vacuoles or similar vesicles 
since incubation of cells with colchicine, a microtubule disrupt­
ing agent, has been shown to slow down the elastin secretion 
[26]. 
It has recently been demonstrated that several proteins syn­
thesized in RER contain a short hydrophobic amino terminal 
sequence, so-called "signal" peptide, which is removed co-trans­
lationally; these precursor forms of proteins are called prepro­
teins [27]. In elastin, in analogy with other proteins, evidence 
for the existence of such a peptide sequence in the primary 
translation product has been presented [14]. Although the exact 
functional roles of the signal sequence are still under discussion, 
there have been 2 suggestions. First, the hydrophobic signal 
sequence may direct the attachment and transport of nascent 
polypeptides from the membrane of RER into the cisternae. 
Secondly, recent evidence suggests that the removal of the 
signal sequence may be essential for normal secretion of the 
protein out of the cell (see reference 5). 
One of the concepts advanced by recent research on protein 
chemistry suggests that proteins which are secreted into the 
extracellular milieu are initially synthesized as nonfunctional 
preCLUsor forms considerably larger than the final molecules. 
Subsequently, the precursor forms are converted to functional 
extracellular proteins by specific proteolytic cleavages. It was 
initially speculated that elastin was derived from a comparable 
high molecular weight precursor form, "proelastin." As we know 
now, however, elastin is not synthesized as a high-molecular 
weight precursor, and the newly synthesized protein is of the 
same size as the secreted protein monomer found in the extra­
cellular space [28]. 
Following the release of elastin chains into the RER, the 
newly synthesized polypeptides undergo a posttranslational 
modification leading to formation of 4-hydroxyproline. The 
TABLE I. Biogenesis and degradation of elastin 
I. Expression of genes coding for elastin polypeptides 
a. Gene selection-
b. Transcription 
c. Processing of the mRNA precursor-
d. Translation 
e. Control of the rate of transcription, mRNA processing and translation 
II. Intracellular Co-translational and Post-translational Modifications 
a. Removal of the signal sequence-
b. Formation of 4-hydroxyproline 
c. Intracellular degradation of some of the polypeptides 
Ill. Secretion 
IV. Extracellular Post-translational Modifications 
a. Oxidative deamination of some lysyl residues 
V. Fiber Formation 
a. Assembly with the microfibrillar protein 
b. Formation of covalent cross-links 
c. Interactions with other extracellular macromolecules and cells 
VI. Extracellular Degradation 
a. Cleavage by specific elastases and other proteolytic enzymes 
Determines the elastin isotype to be synthesized 
Formation of mRNA precursor 
Formation of functional mRNA 
Assembly of polypeptide chains 
Determines the quantity of peptide synthesis 
May be necessary for secretion 
Unknown 
Removal of defective polypeptides and modulation of 
elastin production 
Transport through Golgi apparatus to the extracellu­
lar space 
Necessary for cross-link formation 
Formation of elastic fibers 
Stabilization of the fibers 
Determines the physical chemical properties of tissues 
Turnover of the extracellular fibers 
t These are the major steps in the sequence they are likely to occur in vivo; the steps marked by an asterisk have not been explored in detail 
in case of elastin, but in analogy with other proteins they are likely to occur. 
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synthesis of 4-hydroxyproline is catalyzed enzymatically, since 
incubation of cells with lX, lX' -dipyridyl, an iron chelator which 
inhibits prolyl hydroxylase, abolishes the prolyl hydroxylation 
in elastin [25,29]. Under normal situations, the relative content 
of hydroxyproline in elastin is highly variable, varying from 7 
to 25 residues per 1,000 amino acids. In contrast to collagen, 
hydroxyproline in elastin may not play a critical role in stabi­
lizing the protein conformation, and it has been demonstrated 
that the inhibition of hydroxyproline formation does not inter­
fere with the synthesis or secretion of elastin [26]. It is possible, 
therefore, that the presence of 4-hydroxyproline in elastin is 
only a coincidental feature, perhaps a result of the synthesis of 
both collagen and elastin in the same compartment of the HER 
containing prolyl hydroxylase. On the other hand, the variabil­
ity of hydroxyproline content in elastin may have consequences 
in terms of extracellular fiber formation. Specifically, prelimi­
nary results suggest that hydroxylation of proline may inhibit 
the elastin fibrillogenesis (Abraham P A, Perejda AJ, and U itt 
.J, unpublished observation) [ao]. Although this point has to be 
examined in detail, this mechanism could account for functional 
differences of elastin in various tissues and may play a role in 
disease processes (see below). 
An important posttranslational modification of elastin, the 
oxidative deamiitation of certain lysyl residues to form alde­
hydes takes place in the extracellular space; subsequently, these 
aldehydes participate in cross- link formation (see above). The 
oxidative deamination of lysyl residues is catalyzed by lysyl 
oxidase, which requires copper and molecular oxygen as cofac­
tors [20,31]. Lysyl oxidase has been shown to be synthesized 
and secreted by human skin fibroblasts in culture and, there­
fore, these cells are presumably one source of the enzyme in 
t'il'O [:32 J. 
Def{radation 
Although the metabolic turnover of connective tissue pro­
teins, and especially of elastin, is relatively slow as compared to 
proteins in general, it is clear that a portion' of elastin is 
continuously degraded and replaced by newly-synthesized pro­
teins [a:l J. In addition, degradation of elastin is markedly in­
creased in a v,ariety of pathologic conditions (see below). Thus, 
the tissues containing elastin must contain proteolytic enzymes, 
elastases, which are able to degrade elastic fibers. In general, 
elastases are serine proteinases, and they degrade elastin at 
neutral or slightly alkaline pH [a4,35]. The activity of these 
enzymes can be inhibited by serum factors, such as lX 1 -antipro­
teinase and lX2-macroglobulin. Assay of the amino acids in the 
amino terminus of the degradation products of elastin demon­
strates that these enzymes preferentially cleave polypeptides at 
bonds involving glycine, alanine and valine. Peptide mapping 
of the degradation products has demonstrated, however, that 
the specificity of these enzymes varies from source to source, 
eg, pancreas or polymorphonuclear leukocytes [:36]. 
ELASTIC FIBERS IN DISEASES 
Definition of "Elastin Disease" 
On the basis of the discussion presented above on the metab­
olism of elastin in normal conditions, it is clear that synthesis, 
fibrillogenesis, and degradation of this protein involves several 
steps, many of which are enzymatically mediated. The com­
plexity of elastin metabolism allows us to specify several distinct 
levels at which errors could be introduced into the structure of 
the elastin molecule. Also, structural abnormalities manifesting 
as functional deficiencies may similarly occur in the enzymes 
involved in elastin synthesis and degradation. The latter situa­
tion could lead to synthesis of structurally abnormal elastin 
molecules, or alternatively, could lead to an imbalance in turn­
over of otherwise normal elastic fibers. On the basis of these 
considerationI', we suggest that the term "elastin disease" 
should be applied to pathologic conditions in which elastin or 
the enzymes participating in its metabolism are abnormal. In 
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accordance with the definition of "collagen disease" such a term 
should be restricted to those conditions in which such a defect 
can be clearly demonstrated on the molecular level. Based on 
our current knowledge of elastin in diseases, we are listing in 
Table II those inherited and acquired " elastin diseases" which 
have cutaneous manifestations, and some of them are discussed 
below. 
Buschke· Ollendorff Syndrome 
This syndrome consists of cutaneous lesions, known as der­
matofibrosis lenticularis disseminata, and bone dysplasia, 
known as osteopoikilosis [a7,a8]. Clinically, the skin lesions are 
small yellowish papules, or discs, usually in asymmetric distri­
bution on the lower trunk or extremities (Fig 2A). The bone 
lesions are detectable by x-ray as dense, sclerotic areas at the 
ends of long bones and in the pelvis (Fig a). The Buschke­
Ollendorff syndrome is inherited in an autosomal dominant 
fashion with an almost complete penetrance. The expressivity 
of the syndrome is somewhat variable in that individuals either 
with skin lesions alone or only with bone manifestations have 
been reported in families with the syndrome. 
The histopathologic examination of the skin lesions has re­
vealed an accumulation of broad, branching and interlacing 
elastic fibers in mid-dermis (Fig 2B) [a9,40]. By electron mi­
croscopy, some of the elastic fibers appear unusually broad, 
reinforcing the impression obtained by light microscopic ex­
amination (Fig 4A). In some areas, the diameter of the elastic 
fibers is highly variable and the fibers appear peculiarly 
branched (Fig 4B). These unusual elastic fibers are frequently 
found in close proximity to fibroblast-like cells which often 
have a markedly dilated RER (Fig 4C). It should be emphasized 
that these changes are present only in the affected skin while 
the elastic fibers and cells are normal in the unaffected, perile­
sional skin. 
The increased content of elastin in the dermatofibrosis len­
ticularis disseminata lesions has been biochemically demon­
strated by the assay of desmosine, which showed a a- to 7-fold 
increase, as compared to values obtained from unaffected skin 
in the same patients or from healthy matched controls [41]. 
The reasons for the accumulation of elastin in dermis in the 
patients with dermatofibrosis lenticularis disseminata are not 
clear at the present. However, the finding of fibroblast-like cells 
demonstrating marked dilatation of the cisternae of RER sug­
gests that these cells are actively synthesizing elastin. Thus, the 
skin lesions of the Buschke-Ollendorff syndrome are connective 
tissue nevi of the elastin type, and they may arise on the basis 
of locally increased synthesis, rather than reduced degradation 
of elastic fibers [40,41 J. 
The biochemical nature of the osteopoikilotic bone lesions 
which are an integral part of the syndrome, is currently un­
known. It could be speculated that the bone lesions represent 
ectopic elastin accumulations in bone matrix. Alternatively, 
these lesions may not contain elastin, but may be genetically 
closely linked, yet biochemically unrelated to the skin lesions . 
Pseudoxanthoma Elasticum (PXE) 
This systemic connective tissue disorder is perhaps the best 
example of a disease with generalized abnormalities in elastic 
fibers. Clinically, this condition manifests as characteristic skin 
lesions, ocular changes, and widespread vascular abnormalities 
[42]. The cutaneous lesions appear as small yellowish papules 
which tend to coalesce into large, thick, and inelastic plaques 
(Fig 2C). The vascular complications include hypertension, 
intermittent claudication, and weakening of the peripheral 
pulses. The most severe complications arise from recurrent 
bleeding, occurring most frequently in the gastrointestinal tract. 
The ocular changes consist of angioid streaks, i.e., greyish, 
poorly-defined streaks radiating from the fund1,ls of the eye. 
Histopathologic observations of the skin have demonstrated 
that the dermis in PXE is characterized by excessive deposition 
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TABLE II. Clinical featurel1, hi.�topathology, and al1l1ociated biochemical findings in inherited and acquired diseases of the skin with ela.�tin 
abnormalities 
Disease" 
--- -
Buschke�Ollendorff 
syndrome 
l'seudoxanthoma 
elasticum 
Elastosis perforans 
serplgmosa 
Cutis laxa 
Marfan syndrome 
Menkes' syndrome 
Isolated elastomas 
Actinic elastosis 
Major clinical features 
Yellowish dermal papules asso-
ciated with osteopoikilosis 
Yellowish papules coalescing to 
plaques; cardiovascular prob-
lems; angioid streaks 
Hyperkeratotic papules on the 
face and neck 
Loose, sagging skin 
Skeletal and cardiovascular ah-
normalities; loose-jointedness 
and hyperextensible skin 
Tortuosity of the hlood vessels; 
bri tt le hair 
Dermal papules or nodules 
Thickening and furrowing of the 
skin 
Inheritance" 
AD 
AH" 
NH 
AD,AH,XH 
orNH 
AD 
XH 
NH 
NH 
Histopathology 
Increase in thick, branching elas� 
tic fihers in the dermis 
Accumulation of fragmented and 
calcified elastic fibers in mid 
dermis 
Accumulation and transepider­
mal elimination of elastic fi­
bers 
Fragmentation and loss of elastic 
fibers in some patients 
Fragmentation of the elastic 
structures in aorta 
Fragmentation and reduplica­
tion of internal elastic lamina 
Accumulation of thick elastic fi­
bers in dermis 
Accumulat ion of irregularly 
thickened elastic fibers in up­
per dermis 
Biochemical findings related to elas� 
tic fihers" 
Increased desmosine content of 
the skin 
Deposition of calcium apatite 
crystal; excessive accumula ­
tion of glycosaminoglycans on 
elastic fihers 
Decreased desmosine content 
and lvsvl oxidase activit v in 
the ski"; of some pat ients ' 
Decreased desmosine content in 
elastin isolated from aorta of 
one patient 
Decreased lysyl oxidase activi ty 
due to abnormal copper me­
tabolism 
" Most of these conditions represent a group of diseases with clinical, genetic, and hiochemical heterogeneity. 
" AD, autosomal dominant; AH, autosomal recessive; XH, X-linked recessive; NH, not heritable disease . 
. These biochemical abnormalities have been demonstrated only in a limited numher of patients in each group, and it is not known whet her the 
biochemical changes are the same in each patient with any given disease . In fact, in case of cutis laxa and the Marfan syndrome, there is 
considerable evidence for collagen abnormalities in some patients. 
" Few families with autosomal dominant inheritance pattern and rare cases with a distinct acquired form of pseudoxanthoma elasticum have 
been described. 
of abnormal elastic fibers (Fig 2D). In contrast to elastic fibers 
in normal skin or those seen in the skin lesions of the Buschke­
OllendorfI syndrome, elastin in PXE appears fragmented and 
contains calcium hydroxyapatite [43]. It appears likely that 
these changes are responsible for the inelastic nature of the 
affected skin . 
Most cases of PXE are inherited in an autosomal recessive 
pattern [42]. However, a few families with an apparent auto­
somal dominant inheritance, as well as rare acquired cases have 
been reported [44,45]. If a molecular defect in elastin would be 
the primary abnormality in PXE, then in the autosomal domi­
nant form of the disease a structural alteration in the elastic 
fibers would be expected . In the autosomal recessive cases, on 
the other hand, a defect in the enzymes participating in the 
synthesis, cross-linking, or degradation of elastin could possibly 
be the primary cause. 
An alternate mechanism for degradation of the elastic fibers 
involves the possibility that changes in elastin are secondary to 
initially unrelated events, such as abnormal calcium deposition 
on the fibers [46]. The reasons for calcification of the elastic 
fibers are unknown at present. It has been shown, however, by 
both morphologic and biochemical analyses , that in PXE the 
elastic fibers of the dermis contain excessive amounts of pro­
teoglycans and the binding of these compounds to the elastic 
fibers can be demonstrated before there is any evidence of 
calcium deposition [47]. Thus, it has been suggested that the 
presence of abnormal proteoglycans initiates the calcification 
process. On the other hand, another study has suggested that 
skin fibroblasts cultured from patients with PXE secrete exces­
sive amounts of a serine proteinase which degrades high molec­
ular weight proteoglycans [48]. These degradation products 
might then enhance the calcification of elastic fibers by mech­
anisms which are currently unknown. Although the observa-
tions presented above may not be entirely compatible with each 
other, the end result, irrespective of the mechanism, is extensive 
calcification of the elastic fibers. Thus, it is conceivable that 
the calcified fibers, in response to continuous trauma, break 
down and loose their physiologic properties responsible for the 
elastic nature of skin and other tissues. 
Elastosis Perforans Serpiginosa (EPS) 
This cutaneous condition is associated with a variety of 
inherited diseases of connective tissue ; these include the Ehlers­
Danlos syndrome , the Marfan syndrome and osteogenesis im­
perfecta. It is also frequently found in patients with Down's 
syndrome as well as in otherwise healthy individuals [41 J. 
Furthermore, EPS is sometimes manifested in patients un­
dergoing treatment with D-penicillamine, an agent interfering 
with the cross-linking process of elastin and collagen [3 J. Thus, 
the genetic component of the disease and its possible mode of 
inheritance are unclear in EPS. 
Clinically, the skin lesions consist of groups of hyperkeratotic 
papules typically arranged in an archiform configuration on the 
face or neck (Fig 2E). Histopathologic examination of the skin 
reveals the presence of excessive amounts of abnormally thick 
elastic fibers in the dermis, in a manner similar to the lesions of 
dermatofibrosis lenticularis disseminata (Fig 2F). In addition , 
however, the epidermis contains channels which are filled with 
necrotic and degenerated elastic material (Fig 2F). Therefore, 
EPS is a reactive perforating dermatosis characterized by tran­
sepidermal elimination of abnormal elastic material. 
Cutis Laxa 
This relatively rare disorder is genetically heterogeneous, and 
both inherited and acquired forms of the disease have been 
, .... . 
FIG 2. Clinical and histopatholog-ic presentation of the Buschke-Ollendorff syndrome, pseudoxanLhoma elasticum, and elastosis perforans 
serpig-inosa. In Buschke-Ollendorff syndrome , the small dermal papules (A) are hist olog-ically characterized by accumulation of broad interlacing­
elastic fibers (B). In pseudoxanthoma elasticum , the inelastic, thickened skin (e) demonstrates histologically an accumulation of frag-mented 
elastic fibers (IJ). The characteristic skin lesions of el.astosis perforans serpig-inosa U;) demonstrate histolog-ically an accumulation of broad elastic 
fibers in the upper dermis (F). Also, note thp presence of elastic fibers in the epidermis reflecting- transepidermal elimination. (The histolog-ic 
stain is Verhoeff-van Gieson). ( Reproduced with permission from Uitto [:q, Uitto, Santa Cruz, and Eisen r 401 and lJitto et al r 411. 
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FIe 3. Osteopoikilotic bone lesions of the Buschke-Ollendorff syn­
drome appear as roentgenologically detectable densities at the end of 
long bones. 
encountered [42,49]' In case of inheritance, autosomal domi­
nant, autosomal recessive, and X-linked recessive patterns have 
been noted. This disorder primarily affects the skin, but in most 
patients features of generalized connective tissue abnormality 
are present. The skin is pendulous, redundant and stretchable, 
but it is not resilient and does not recoil like the skin of patients 
with the Ehlers-Danlos syndrome. 
In most cases of cutis laxa, the biochemical basis of skin 
changes is unclear, but in several patients, the histopathology 
of the skin suggests that the major abnormality lies in elastin 
[36]. In such cases, the amount of elastic fibers have been shown 
to be reduced and the remaining fibers present in the skin 
appear to be fragmented. Recently, the reduction of elastin in 
the skin of a patient with acquired form of cutis laxa has also 
FIG 4. Electron microscopy of dermis in the lesions of the Buscke­
Ollendorff syndrome. In some areas, the elastic fibers, E, appear unus­
ually broad (A) while in others, the fibers have a peculiar branched 
appearance (B). The fibroblast-like cells demonstrate a markedly dila­
tated rough endoplasmic reticulum suggesting increased synthesis of 
elastin (e). (Reproduced with permission from Vitto et al [41]). 
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been demonstrated by direct desmosine assay (Uitto J, et al: 
unpublished observations). 
In some patients with cutis laxa, there is evidence of abnormal 
cross-linking of both elastin and collagen [50]. Specifically, 2 
patients with X-linked recessive cutis laxa have been found to 
have deficient lysyl oxidase activity in cultured skin fibroblasts 
[51]. This observation, together with an increased solubility of 
collagen, suggests that defective cross-link formation contrib­
utes to the connective tissue weakness in these patients. It 
should be noted, that the concentration of serum copper was 
also low. Since copper is a co-factor for lysyl oxidase and 
experimental copper deficiency produces a clinical picture sim­
ilar to that seen in the patients with X-linked cutis laxa [31], 
the primary defect in these cases might reside in deficient 
copper metabolism. It is not known if other cases of cutis laxa 
have a similar defect in lysyl oxidase activity, and further 
studies are required to disclose the underlying biochemical 
defects in various forms of this syndrome. 
Marfan Syndrome 
This syndrome, inherited in an autosomal dominant fashion, 
is a prototype of heritable disorders of connective tissue [42]. 
Clinically, the Marfan syndrome consists of skeletal, ocular, 
cardiovascular, and dermatologic abnormalities [41,52]. In the 
classic, so-called aesthenic-form, the skeletal manifestations 
include tall stature, dolichostenomelia, arachnodactyly, pectus 
excavatum or carinatum, and kyphoscoliosis. Ocular abnormal­
ities include myopia and congenital dislocation of the lens, the 
displacement being usually upward. The cardiovascular abnor­
malities, the most severe manifestations of the disease, include 
aneurysms and dissection of the aorta. The rupture of the aorta 
is the most common cause of premature demise in the Marfan 
syndrome. The patients also have a variety of heart valve 
abnormalities, mitral valve prolapse, and regurgitation being 
the most common ones. The skin lesions of the Marfan syn­
drome include striae distensae, and elastosis perforans serpigi­
nosa. 
At least 2 clinically distinct subsets can be separated from 
the classic, aesthenic form of the disease. Although moderate 
loose-jointedness is part of the clinical picture in the Marfan 
syndrome, some of the patients with typical Marfanoid habitus 
have a strikingly increased hypermobility of the joints. This 
variety is known as the Marfanoid hypermobility syndrome. On 
the other hand, another group of patients with typical features 
of the Marfan syndrome have exceptionally tight joints with 
contractures of the hands and fingers. This particular group of 
patients, known as contractural arachnodactyly, has less fre­
quent association of cardiovascular problems. 
Because of the similarity of the clinical findings of the Marfan 
syndrome to experimental lathyrism, a cross-linking defect, 
either in collagen or elastin, or both, has been postulated in 
these patients. In fact, some investigations have suggested that 
cross-linking of collagen in the Marfan syndrome may be ab­
normal. Specifically, the collagen in skin or in skin fibroblast 
cultures is more extractable in aqueous or denaturing solvents 
than collagen in the controls [3,53]. However, lysyl oxidase 
activity has been reported to be normal in cultured skin fibro­
blasts with this syndrome [:32]. On the other hand, a recent in 
uitro study of aorta collagen in one patient with the Marfan 
syndrome has suggested that an insufficient synthesis of type I 
collagen, rather than a cross-linking defect, may be the under­
lying defect [54]. Ai'lO, a quantitative defect in a2-chain pro­
duction of type I collagen was noted in one patient with Marfan 
syndrome [55 J. Examination of aorta extract by SDS-polyacryl­
amide electrophoresis revealed 2 separate bands in the a2 
region, and an increase in the al(I)/a2 ratio was noted [55]. 
These changes were accompanied by increased solubility of 
skin collagen in 1 M NaCI or 0.5 M acetic acid. The investigators 
�1Uggested, therefore, that decreased synthesis of a2-chains leads 
to decreased cross-linking of collagen, which subsequently 
causes the weakness of connective tissues. It should be men-
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tioned that in this study, abnormal a2-chain synthesis was 
noted only in one patient while type I collagen appeared to be 
normal in several additional patients examined. 
We have recently studied the connective tissues of aorta from 
a patient with classic presentation of the Marfan syndrome 
[63]. The patient died at the age of 34 from complications of 
surgery performed for replacement of the aortic valve. In au­
topsy, several dissecting and saccular aneurysms of the aorta 
were noted, and histologically, the elastin appeared fragmented. 
Tensile strength of the aortic rings as measured with stretch­
strain device was markedly reduced, as compared with controls. 
Amino acid analyses indicated that elastin isolated from aorta 
was exceptionally low in desmosine, as compared with controls. 
Interestingly, the content of hydroxyproline in elastin was high 
in the Marfan patient being 25.0 residues per 1000 vs 8.5 in the 
control. These results suggest that deficient cross-linking of 
elastin in this patient might be responsible for reduced tensile 
strength of the aorta. It is unclear, however, whether the 
increased hydroxyproline content of elastin might have played 
an etiologic role in the deficient cross-linking, in a manner 
discussed above. It should be mentioned that the solubility of 
collagen was unchanged. Thus, this appears to be the first 
demonstration of a molecular defect in elastin in patients with 
Marfan syndrome. Since previous studies [53-55] have dem­
onstrated defects in collagen, it appears that the Marfan syn­
drome comprises of a group of diseases with diverse underlying 
defects in collagen and elastin. 
Menkes Syndrome 
This condition, inherited in an x-linked recessive manner, 
involves abnormalities in the elastic fibers. Clinically, the pa­
tients have typical facies, and common systemic manifestations 
include hypothermia, vascular insufficiency, and susceptibility 
to infections. Characteristically, the hair is hypopigmented, 
brittle, and shows pili-torti [56]. The histopathologic examina­
tion of the arteries shows fragmentation and reduplication of 
the internal elastic lamina [57]. The basic defect in the Menkes 
syndrome appears to be an abnormality in the transport of 
copper across the cell membranes, and intestinal absorption of 
copper is reduced leading to low levels in serum and other 
extracellular compartments. It has been recently demonstrated 
that the activity of lysyl oxidase in fibroblasts derived from 
patients with Menkes syndrome is markedly reduced [58]. 
Thus, the basis of connective tissue manifestations of the 
Menkes syndrome could be defective cross-linking of elastin 
and collagen. 
ACQUIRED DISEASES 
Aberrations in the elastic fibers have also been demonstrated 
in a variety of acquired conditions, and in the skin, isolated 
elastomas or actinic elastosis could serve as examples of such 
processes [41,43]. The isolated elastomas are histologically 
characterized by an accumulation of elastic fibers in a similar 
manner as is seen in dermatofibrosis lenticularis disseminata in 
BWlchke-Ollendorff syndrome (see Fig 2B). In actinic elastosis, 
on the other hand, the dermis is characterized by excessive 
amounts of elastic fibers which are fragmented; the histologic 
picture is somewhat reminiscent of that seen in PXE (see Fig 
2D). The biochemical basis of these 2 acquired conditions is 
largely unknown. 
In addition to skin disorders, abnormalities in elastic fibers 
have been encountered in other pathologic processes, particu­
larly in those involving blood vessels and lungs [59-61]. For 
instance, changes in elastic fibers most likely contribute to 
degeneration of aorta and other blood vessels during aging and 
also in arteriosclerotic processes. In these conditions, it has 
been suggested that increased activity of elastolytic enzymes is 
responsible for degenerative changes of the aorta. Elastases also 
play an important role in the development of pulmonary em­
physema, and perhaps in the invasion of malignant tumors into 
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the surrounding connective tissue. Finally, an elastase present 
in polymorphonuclear leukocytes most likely participates in the 
development of vascular lesions in inflammatory processes, 
such as leukocytoclastic vasculitis [62]. 
In conclusion, recent years have witnessed progress in under­
standing the basic biochemistry of elastin. In some disease 
entities definite changes are known to occur in the structure of 
elastin, but the mapping of the specific biochemical defects 
underlying the clinical abnormalities is still incomplete. Con­
sequently, further work is clearly needed to define the distinct 
role of elastin in inherited and acquired diseases affecting the 
skin' and other connective tissues. 
Some of the illustrations were kindly provided by Drs. Arthur Z.  
Eisen, William A. M urphy, a n d  Daniel J. Santa Cruz, Washington 
U niversity School of M edicine. 
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